Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00019097 | Vaccine Therapy in Treating Patients With Multiple Myeloma | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT05712967 | Role of the Host Microbiota and Il-17 in Favoring Multiple Myeloma Progression(MICRO-MM) | completed | — | 62 | IRCCS San RaffaeleOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT04671251 | Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 13 | Avalo Therapeutics, Inc.INDUSTRY | 1 | Feb 29, 2024 | clinicaltrials |
| NCT04695366 | The Potential of Patient-reported Outcome Measures in Detection of Relapse in Diffuse Large B-cell Lymphoma | completed | — | 250 | Herlev HospitalOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06271369 | Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study. | completed | — | 613 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT02056756 | Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 63 | Stichting European Myeloma NetworkNETWORK | 2 | Feb 20, 2024 | clinicaltrials |
| NCT03406091 | Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients | completed | — | 300 | Fondazione EMN Italy OnlusOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT04478123 | Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer | completed | Phase 2 | 62 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT01995708 | CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation | completed | Phase 1 | 28 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT04858568 | Immune Responses to COVID-19 Vaccination in Lymphoma Patients(PROSECO) | completed | — | 592 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT02561962 | A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 42 | AmgenINDUSTRY | 2 | Feb 1, 2024 | clinicaltrials |
| NCT01270009 | Role of BCL-B in Multiple Myeloma | completed | — | 60 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT04683393 | A Single-centre Prospective Study to Explore the Role of Frailty in Patients With Multiple Myeloma. | completed | — | 110 | Manchester University NHS Foundation TrustOTHER_GOV | 0 | Jan 24, 2024 | clinicaltrials |
| NCT01190787 | Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone | completed | Phase 2 | 150 | European Myeloma Network B.V.NETWORK | 1 | Jan 23, 2024 | clinicaltrials |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | completed | Phase 1 / Phase 2 | 133 | CytomX TherapeuticsINDUSTRY | 4 | Jan 23, 2024 | clinicaltrials |
| NCT03976102 | Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma(FLINTER) | completed | Phase 3 | 317 | Dr. Reddy's Laboratories LimitedINDUSTRY | 1 | Jan 22, 2024 | clinicaltrials |
| NCT02658968 | Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) | completed | Phase 1 | 18 | Nordic NanovectorINDUSTRY | 5 | Jan 16, 2024 | clinicaltrials |
| NCT03833180 | A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | completed | Phase 1 | 91 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jan 12, 2024 | clinicaltrials |
| NCT01394640 | Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic Patients | completed | — | 124 | Paolo CorradiniOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT03128359 | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant | completed | Phase 2 | 38 | City of Hope Medical CenterOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT03506360 | Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 2 | 13 | Mayo ClinicOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT03399513 | Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma(R-CHOEP-brut) | completed | Phase 2 | 40 | University Hospital MuensterOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT01454297 | Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile(CoMMpass) | completed | — | 1,154 | Multiple Myeloma Research FoundationOTHER | 3 | Jan 3, 2024 | clinicaltrials |
| NCT02697344 | Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma | completed | Phase 1 | 10 | Mayo ClinicOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT04361279 | A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL | completed | Phase 3 | 421 | Shanghai Institute Of Biological ProductsINDUSTRY | 1 | Dec 27, 2023 | clinicaltrials |
| NCT04439006 | Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization | completed | Phase 1 | 10 | Jennifer WoyachOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT00520767 | Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease | completed | Phase 2 | 35 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT03806179 | Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL(LYMRIT-37-07) | completed | Phase 1 | 7 | Nordic NanovectorINDUSTRY | 2 | Dec 22, 2023 | clinicaltrials |
| NCT05028374 | COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies | completed | Phase 2 | 119 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT04682405 | Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM) | completed | Phase 2 | 51 | Washington University School of MedicineOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT06170151 | Role of18F-FDG PET-CT for Assessing and Predicting Response to Daratumumab and for Prognosis With Multiple Myeloma | completed | — | 10 | IRCCS San RaffaeleOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT01913730 | Maintenance Therapy With Subcutaneous Bortezomib | completed | Phase 2 | 63 | European Myeloma Network B.V.NETWORK | 1 | Dec 13, 2023 | clinicaltrials |
| NCT01421524 | Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma | completed | Phase 1 | 271 | CelgeneINDUSTRY | 5 | Dec 12, 2023 | clinicaltrials |
| NCT06153576 | The Value of Systematic Biopsies During Vertebroplasty for the Treatment of Osteoporotic Vertebral Fractures | completed | — | 1,120 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT04121260 | A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma | completed | Phase 1 | 21 | Janssen Research & Development, LLCINDUSTRY | 1 | Dec 8, 2023 | clinicaltrials |
| NCT03169361 | NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma" | completed | — | 774 | TakedaINDUSTRY | 1 | Dec 7, 2023 | clinicaltrials |
| NCT04703985 | Evaluation of the Success of Prophylactic Enteral Nutrition in Therapeutic Intensification With Autograft of Autologous Hematopoietic Cells in Hematology(GAGNE) | completed | — | 200 | University Hospital, BordeauxOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT01393756 | Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma(R2-CHOP2) | completed | Phase 2 | 80 | The Lymphoma Academic Research OrganisationOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02843074 | Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients | completed | Phase 2 | 53 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT00697684 | Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant | completed | Phase 1 | 29 | Beth Israel Deaconess Medical CenterOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT01145209 | Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL | completed | Phase 2 | 32 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Nov 28, 2023 | clinicaltrials |
| NCT03072771 | Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | completed | Phase 1 | 14 | Washington University School of MedicineOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT03255018 | Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Nov 28, 2023 | clinicaltrials |
| NCT02834364 | BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)(GMMG-BIRMA) | completed | Phase 2 | 12 | University of Heidelberg Medical CenterOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT03224507 | Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma(MASTER) | completed | Phase 2 | 123 | University of Alabama at BirminghamOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT01523223 | Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies | completed | Phase 1 | 16 | Robert LowskyOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT04812691 | CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma | completed | Phase 1 | 12 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 22, 2023 | clinicaltrials |
| NCT04853277 | Patient Reported Outcomes and Patient Education in Cellular Therapy Patients | completed | N/A | 31 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Nov 22, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Mar 4, 2024source: clinicaltrials